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Abstract  
We have previously demonstrated inverse associations between maternal 25(OH)-vitamin D status and 
perinatal DNA methylation at the retinoid-X-receptor-alpha (RXRA) locus and between RXRA 
methylation and offspring bone mass. We therefore used an existing randomised trial to test the 
hypothesis that maternal gestational vitamin D supplementation would lead to reduced perinatal RXRA 
locus DNA methylation. The Maternal Vitamin D Osteoporosis Study (MAVIDOS) was a multicentre, 
double-blind, randomised, placebo-controlled trial of 1000IU/day cholecalciferol or matched placebo 
from 14 weeks¶ gestation until delivery. Umbilical cord (fetal) tissue was collected at birth and frozen 
at -80oC (n=453). Pyrosequencing was used to undertake DNA methylation analysis at 10 CpG sites 
within the RXRA locus (identified previously). T-tests were used to assess differences between treatment 
groups in methylation at the three most representative CpG sites.  Overall, methylation levels were 
significantly lower in the umbilical cord from offspring of cholecalciferol-supplemented mothers, 
reaching statistical significance at four CpG sites, represented by CpG5: mean difference in % 
methylation between the supplemented and placebo groups was -1.98% (95%CI: -3.65 to -0.32, 
p=0.02). ENCODE evidence supports functionality of this locus with strong DNase hypersensitivity 
and enhancer chromatin within biologically relevant cell types including osteoblasts. Enrichment of the 
enhancer-related H3K4me1 histone mark is also seen in this region, as are binding sites for a range of 
transcription factors with roles in cell proliferation, response to stress and growth factors. Our findings 
are consistent with previous observational results and provide new evidence that maternal gestational 
supplementation with cholecalciferol leads to altered perinatal epigenetic marking, informing 
mechanistic understanding of early life mechanisms related to maternal vitamin D status, epigenetic 
marks and bone development. This article is protected by copyright. All rights reserved 
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Introduction 
It is becoming increasingly well recognised that environmental factors acting through epigenetic 
mechanisms induce persistent changes in gene expression, leading to differences in phenotype.(1, 2) 
Various examples of such epigenetic mechanisms have come from the natural world, and also from 
experimental animal studies. For example, altered pregnancy diet in rats has been shown to lead to 
modification of DNA methylation, gene expression, and phenotype in the offspring.(1-4) Evidence for 
the relevance of such mechanisms in human disease is increasing, and we have recently documented 
associations between perinatal DNA methylation at particular loci and bone phenotype in the 
offspring.(5, 6) Thus we have previously demonstrated that methylation at the cyclin-dependent kinase 
inhibitor 2A (CDKN2A)(6) and retinoid-X-receptor-alpha (RXRA)(5) loci in umbilical cord DNA was 
associated with offspring bone mass in childhood in the Southampton Women's Survey (SWS) mother-
offspring cohort. RXRA is an essential part of vitamin D signalling, forming a heterodimer with the 
vitamin D receptor (VDR) in the nuclear action of 1,25(OH)2-vitamin D. We thus reasoned that this 
latter observation might be of key relevance to our demonstrations of associations between maternal 
25(OH)-vitamin D status in pregnancy and offspring bone mass(7-9) together with our finding of a 
positive effect of maternal vitamin D supplementation during pregnancy on neonatal bone mass for 
winter births (when background 25(OH)-vitamin D concentrations are lowest).(10) In the SWS, 
methylation at one CpG site upstream of the RXRA promoter was associated with a marker of maternal 
pregnancy 25(OH)-vitamin D status, with greater 25(OH)-vitamin D status associated with lower RXRA 
promoter methylation.(5) Clearly, causation cannot be concluded from an observational study, and 
therefore we hypothesized, in the setting of the Maternal Vitamin D Osteoporosis Study (MAVIDOS) 
randomised, double-blind, placebo-controlled trial of vitamin D supplementation in pregnancy,(10) that 
this intervention would lead to reduced RXRA DNA methylation in umbilical cord tissue at birth 
compared with placebo.  
  
Participants and Methods 
Participants: The Maternal Vitamin D Osteoporosis Study (MAVIDOS) 
We analysed RXRA DNA methylation data from the MAVIDOS study, a multicentre, double-blind, 
randomised, placebo-controlled trial of vitamin D supplementation in pregnancy, in which the primary 
outcome was neonatal bone mass.  A detailed description of the study methods and primary findings 
have been published previously.(10, 11)  The study was approved by the Southampton and South West 
Hampshire Research Ethics Committee.  MAVIDOS was registered prospectively (ISRCTN:82927713; 
EUDRACT:2007-001716-23) with full approval from the UK MHRA. Written, informed consent was 
obtained from all participants. 
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To briefly summarise the trial protocol:(10, 11) women attending one of three United Kingdom (UK) 
hospitals [University Hospital Southampton NHS Foundation Trust, Southampton, UK; Oxford 
University Hospitals NHS Foundation Trust, Oxford, UK; Sheffield Hospitals NHS Trust (University 
of Sheffield), Sheffield, UK] for early pregnancy ultrasound screening (11- ZHHNV¶ JHVWDWLRQ
between 6th October 2008 and 11th February 2014 were invited to participate in the study.   Inclusion 
criteria were: age over 18 years, singleton pregnancy, and gestation less than 17 weeks based on last 
menstrual period and ultrasound measurements.  Exclusion criteria included: women with known 
metabolic bone disease, renal stones, hyperparathyroidism or hypercalciuria, those taking medication 
known to interfere with fetal growth, fetal anomalies on ultrasonography and women already using 
>400IU/day vitamin D supplementation.  A screening blood sample was obtained and analysed on the 
local NHS platform [all three laboratories (Southampton, Oxford and Sheffield) participate in DEQAS 
vitamin D quality assurance system (http://www.deqas.org/)]; women with 25(OH)D between 25 and 
100nmol/l and serum calcium <2.75mmol/l were eligible to enrol fully in the study. 
Participants were randomised to receive either cholecalciferol 1000IU/day or matched placebo [Merck 
KGaA, (Darmstadt, Germany)/ Sharp Clinical Services (Crickhowell, UK; previously DHP-Bilcare)], 
from EHIRUHZHHNV¶JHVWDWLRQ until delivery.   Packs of study treatment were randomly assigned in a 
1:1 ratio by Sharp Clinical Services using a computer-generated sequence in randomly permuted blocks 
of ten, starting randomly midway through the block, and sequentially numbered, before delivery to the 
study sites, and then dispensed in order by each study pharmacist. The study medication was provided 
in a blister pack in a single box containing all medication for the whole pregnancy.  The participants, 
those providing antenatal and intrapartum care, and all field researchers involved in data collection and 
sample analysis were blinded to the intervention.  All participants received standard antenatal care, and 
could continue self-administration of dietary supplements containing up to 400IU/day vitamin D.   
Maternal assessments during pregnancy 
The participants attended the research centre for a detailed assessment of diet (including supplement 
use), lifestyle (smoking, physical activity participation, employment) and health (past medical history, 
current medication use) using interviewer-led questionnaires both prior to commencing the study 
medication, and aJDLQDWZHHNV¶JHVWDWLRQ  Ethnicity was reported by the participant and categorized 
as µZhite¶ or µnon-white¶.    
Assessment of 25(OH)D status 
A non-fasted venous blood sample was obtained on the day that the study medication was dispensed 
and also DW  ZHHNV¶ JHVWDWLRQ; serum was stored at -80°C.  25(OH)D was assessed by 
chemiluminescent assay (Liaison automated platform, Diasorin, Minnesota, USA).  All samples were 
analysed in a single batch at the end of the study at MRC Human Nutrition Research, Cambridge, UK.  
Details of assay performance and quality control through participation in the Vitamin D External 
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Quality Assessment Scheme (DEQAS), National Institute of Standards and Technology (NIST) and the 
United Kingdom National External Quality Assessment Service (NEQAS) are given elsewhere.(12, 13)  
Neonatal DXA 
All neonates underwent DXA assessment at whole body minus head and lumbar spine sites (Hologic 
Discovery, Hologic Inc, Bedford, MA, USA, or GE-Lunar iDXA, GE-Lunar, Madison, WI, USA, with 
neonatal software) within two weeks of birth. The current analysis uses the whole body minus head 
measures. The infant was undressed, clothed in a standard towel, fed and pacified before the assessment. 
Each instrument underwent daily quality control, with cross-calibration between sites. The total 
UDGLDWLRQGRVH ZDV HVWLPDWHG WR EH ā P6Y HTXLYDOHQW WR DERXW  GD\V¶ H[SRVXre to background 
radiation in the UK. All DXA images were reviewed for movement artefacts and quality by two 
operators (NCH and RJM), who were blinded to treatment allocation.  
Umbilical Cord DNA extraction 
Immediately following delivery, a 5-10 cm segment was cut from the mid portion of each cord, flushed 
with saline to remove fetal blood, flash-frozen in liquid nitrogen DQGVWRUHGDWí&XQWLOUHTXLUHGIRU
DNA isolation. Genomic DNA was isolated from frozen archived umbilical cord tissue by classical 
proteinase K digestion and phenol:chloroform extraction. 
Quantitative DNA methylation analysis and pyrosequencing  
The region of interest is in close proximity of the RXRA gene locus, 2,252 base pairs upstream from the 
transcriptional start site. It contains 12 CpG dinucleotides (chr9: 137215735- 137216064, Human 
genome hg19/GRCh37 build) (Online Supplementary Figure 1). We used sodium bisulfite targeted 
pyrosequencing (Pyromark MD, Qiagen; 
https://www.qiagen.com/fi/resources/technologies/pyrosequencing-resource-center/technology-
overview/)(14) to carry out in-depth analysis of the methylation status of 10 out of 12 CpGs within the 
previously identified differentially methylated region of RXRA in umbilical cords. Pyrosequencing was 
not performed on CpGs 6 and 7 (at genomic coordinates (hg19) chr9 137215867 and 137215956 
respectively) for sample conservation purposes due to their distance from other CpGs (therefore 
requiring separate amplicons), as shown in Online Supplementary Figure 1.  Inter- and intra-plate 
controls were added to each plate as a control for inter- and intra-plate variability, and 0% and 100% 
methylation controls were run to ensure that the full range of methylation could be detected.  The 
genomic coordinates for the RXRA CpG sites are shown in Online Supplementary Table 1.  
Statistical Analysis 
Women and babies who had umbilical cord RXRA pyrosequencing analysis and had delivered a liveborn 
infant, were included in the analysis.  All outcomes were assessed for normality using visual inspection 
of histograms. Percentage DNA methylation at all RXRA CpGs analysed was normally distributed, 
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except at CpGs 1 and 3.  Characteristics of the women in the two treatment arms were compared using 
t-tests, Mann-:KLWQH\8DQGȤ2 tests for normally distributed, non-normally distributed and categorical 
variables, respectively. Characteristics of the MAVIDOS babies (boys versus girls) for whom neonatal 
DXA and RXRA methylation data were available were also compared. Neonatal DXA indices were 
whole-body minus head bone area (BA), bone mineral content (BMC) and areal bone mineral density 
(BMD), %BMC and size-corrected bone mineral content [scBMC=BMC adjusted for BA, height and 
weight (to minimise the effect of body size)]. Continuous child characteristics were summarised using 
mean (SD) or median (interquartile range [IQR]). Categorical variables were summarised using 
percentages. Differences in continuous variables between boys and girls were tested using t-tests or 
Mann-Whitney U-tests where appropriate. All participants were analysed by the group to which they 
were originally randomised.  Differences in RXRA DNA methylation between the two treatment groups 
were compared using t-tests or Mann-Whitney U tests for normally distributed and non-normally 
distributed variables respectively. RXRA methylation was Fisher-Yates transformed to standard 
deviations. Separate linear regression analyses were carried out to analyse the difference in methylation 
between the treatment groups. We analysed the interaction between treatment group, RXRA methylation 
and season of birth due to previously described seasonal variations in 25(OH)D concentrations reported 
in many previous studies. To ensure adequate sample sizes, we defined season of birth as a binary 
variable using the UK Meteorological Office classification, combining winter (December to February) 
with spring (March to May)WRJLYHDQRYHUDOO³ZLQWHU´YDULDEOH (December-May), and summer (June 
to August), with autumn (September to November) WR JLYH DQ RYHUDOO ³VXPPHU´ YDULDEOH (June-
November). To explore associations between RXRA methylation and bone outcomes, linear regression 
analyses were carried out, adjusted for treatment group and sex where appropriate.   
Based on previous findings, we recognised that there was likely to be co-linearity between the individual 
exposures and outcomes,(5, 6) so we undertook a data reduction approach by investigating clustering of 
the CpG methylation.(6) Our approach is appropriate given the relatively small number of tests in our 
analysis, compared with larger scale genome-wide associations studies, for which methods such as 
Bonferroni or the Benjamini-Hochberg/ False Discovery Rate corrections for multiple testing would be 
appropriate.(15) Previous studies have shown that where clusters of differential CpGs can be identified, 
they are more likely to be of functional relevance than are individual CpG changes.(16) By investigating 
the correlation between methylation at each of the individual CpG sites (Online Supplementary Table 
2) and calculating the median absolute deviation (MAD) from the median for each site (Online 
Supplementary Table 3), we grouped the CpG sites into 3 clusters (CpGs1-5, 8-11, 12), with each cluster 
represented by the site with the highest MAD score (i.e. the site with the greatest variability within the 
cluster), that is, CpG sites 5, 11, and 12 respectively. For completeness, we also used the Simes 
modification of the Bonferroni method to undertake a p-value correction on the analyses, using the Stata 
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³TTYDOXH´FRPPDQGZKLFKLVVLPLODUWRWKH³SDGMXVW´FRPPDQGLQ57KHVHDUHSUHVHQWHGDVT-values 
in the relevant results tables. 
Further biological support for this clustering was provided by exploration of the ENCODE data(17), 
demonstrating distinct DNase I hypersensitivity sites at either end of the differentially methylated 
region, and discrete grouping of transcription factor binding. All analyses were performed in Stata v14 
(Statacorp, College Station, Texas, USA).  A p-value of <0.05 was considered statistically significant.  
 
Results 
Characteristics of participants 
965 women (85%) remained in the study until delivery (Figure 1).(10) There were 486 live births in the 
control group and 479 in the cholecalciferol group, of which 228 and 225 umbilical cords respectively 
underwent pyrosequencing of the RXRA region of interest.   78 babies for whom pyrosequencing results 
were available did not have a useable DXA scan (43 randomised to placebo, 35 to cholecalciferol), 
leaving a remaining 375 babies with RXRA methylation analysis, DXA outcomes and the relevant 
maternal information. Of the 453 women included in the initial analysis, the mean (SD) age at delivery 
was 30.9 (5.2) years in the placebo group and 30.7 (5.1) years in the cholecalciferol supplemented 
group. Baseline characteristics of women in the placebo and cholecalciferol groups at randomisation 
were similar (Table 1a). Neonatal DXA whole body minus head bone and body composition 
measurements were available for 201 boys (91 born to mothers randomised to placebo, 110 to 
cholecalciferol) and 174 girls (94 born to mothers randomised to placebo, 80 to cholecalciferol), (Table 
1b). A Chi-Squared test demonstrated no difference in the sex distribution of the treatment groups. 
There was no difference in gestational age between the boys and girls. As would be expected, boys had 
a greater average whole body minus head bone mineral content (BMC, g) and bone area (BA, cm2) than 
girls. In this subset of the MAVIDOS trial population, no differences in gestational age or whole body 
minus head DXA outcomes were observed in the babies by maternal randomisation group to placebo 
or 1000 IU cholecalciferol (Table 1c). 
Cholecalciferol supplementation and perinatal RXRA methylation 
Percentage methylation at the RXRA Differentially Methylated Region (DMR) varied greatly across the 
ten CpG sites measured, for example ranging from 29.0% to 81.4% at CpG 5 (mean 47.7%, SD 9.0%) 
(Online Supplementary Table 1). However, percentage methylation tended to be lower in the 
cholecalciferol supplemented group than in the placebo group (Figure 2). At CpG 5 (representing 
CpGs1-5), mean (SD) percentage methylation was 46.7 (8.2) % in the cholecalciferol group and 48.7 
(9.7) % in the placebo group, mean difference -1.98 percentage points, p=0.02. Whilst percentage 
methylation at both CpGs 11 (representing CpGs 8-11) and 12 was lower in cholecalciferol than placebo 
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group births, these differences were not statistically significant (Table 2 and Online Supplementary 
Table 4). We observed no consistent associations between maternal 25(OH)D status at 34 weeks, or 
change in 25(OH)D from early to late pregnancy, and RXRA methylation in umbilical cord tissue across 
the cohort. However, there was evidence of an interaction between change in 25(OH)D between 14 and 
34 weeks gestation 25(OH)D and treatment allocation to cholecalciferol or placebo on RXRA 
methylation at CpG 11 (p=0.022). 
Interactions between season of birth, treatment group and percentage DNA methylation at RXRA 
Greater increases in maternal 25(OH)D status were seen in summer (June-November) than winter 
(December-May) births, with the increase in 25(OH)D during pregnancy being more than double in the 
women giving birth in summer. In summer births, mean (SD) change in 25(OH)D between 14 and 34 
weeks gestation was 8.1 (16.0) nmol/l in the placebo group (n=124), and 28.0 (19.8) nmol/l in the 
vitamin D supplemented group (n=127). In winter births, mean (SD) change in 25(OH)D between 14 
and 34 weeks gestation was -15.0 (17.6) nmol/l in the placebo group (n=103), and 13.6 (22.6) nmol/l 
in the vitamin D supplemented group (n=95). 
There was evidence of statistically significant interactions for the outcome of RXRA methylation 
between treatment allocation (cholecalciferol vs placebo) and season of birth (at all three representative 
CpGs: CpG 5, p=0.02; CpG 11, p=0.009; and CpG 12 p=0.01). The effect of treatment group on RXRA 
methylation appeared greater in summer than winter births (Table 3). In summer births there was a 
difference in percentage methylation at RXRA CpG 5, 11 and 12 between treatment groups ranging from 
-3.69% at CpG 5 (p=0.001), -2.38% at CpG 11 (p=0.02), and -2.13% at CpG 12 (p=0.005), but the 
differences between groups were non-significant for winter births. This interaction persisted after 
adjustment for potential differences in maternal characteristics between the season groups (maternal 
BMI and skinfold thickness), and for other factors known to influence methylation (offspring sex and 
maternal smoking).   
RXRA methylation and offspring bone indices measured by DXA 
In the population as a whole, there were modest positive associations between RXRA methylation at 
CpG 5 and offspring whole body minus head BA, BMC and aBMD (Table 4). However, on stratification 
according to treatment allocation, associations were noted in the placebo but not the cholecalciferol 
supplemented groups, as documented in Figure 3. In the placebo group (red bars in Figure 3), RXRA 
methylation at CpG 11 was positively associated with BA (ȕ=6.96 cm2 per 10% increase in methylation, 
p=0.05). There was also a tendency towards positive associations between methylation and BA at CpG 
5 and CpG 12. Furthermore, again in the placebo group, methylation at CpGs 5 and 11 was positively 
associated with offspring BMC (at CpG 5, ȕ=1.75g per 10% increase in methylation, p=0.03; at CpG 
11, ȕ=2.34g per 10% increase in methylation, p=0.02). Conversely, in the cholecalciferol supplemented 
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group (blue bars in Figure 3), no statistically significant associations were found between methylation 
at CpGs 5, 11 and 12 and offspring neonatal DXA bone outcomes (Online Supplementary Table 5).  
ENCODE Functional Analysis 
The DMR itself resides within the upstream CpG island shore region (within 2kb) of the RXRA ¶&S*
Island. Encyclopedia of DNA elements (ENCODE) consortium data were interrogated for functional 
evidence within this location.(17) This investigation revealed that the region of interest within the RXRA 
locus contains a cluster of DNase I hypersensitive sites (DHS, a general regulatory marker, often found 
within regulatory elements such as promoters and enhancers(18)), identified in 84 cell lines out of 125 
(See Online Supplementary Figure 2, with examples from the chorion and osteoblast cell lines 
highlighted). Furthermore, significant enrichment of the enhancer-related H3K4me1 histone mark 
across a range of tissue types was found both across and within 250bp of the DMR (Online 
Supplementary Figure 2). Enhancer loci may show dynamic DNA methylation indicative of 
transcription factor interaction within these functional regions.(19) Consistent with this, genome 
segmentations from ENCODE (displaying chromatin state segmentations from six cell lines) predict 
weak enhancer activity or an open chromatin cis regulatory element at the RXRA DMR (yellow region 
in Online Supplementary Figure 2) at the RXRA DMR. Finally, ENCODE transcription factor (TF) 
binding data demonstrate significant binding within the RXRA DMR. The numbers of transcription 
factor binding sites found at the RXRA DMR in the ENCODE database vary between cell types, for 
example in the cell line, MCF-7, highly responsive to estrogen and TSH(20), three transcription factors 
bind with high affinity at the RXRA DMR (MYC, CTCF and POL2RA).  In summary, these findings 
suggest the RXRA DMR as a region of significant functional activity across a range of cell types, with 
evidence of strong DNAse I hypersensitivity sites, weak enhancer or cis regulatory element activity, 
and transcription factor binding. 
RXRA methylation and gene expression in vitamin D-treated placental villous fragments 
In order to experimentally investigate the influence of vitamin D on RXRA methylation in perinatal 
tissue (placenta), we collected 6 placentas from healthy term pregnancies, outside the MAVIDOS trial 
(with full ethics approval, REC 11/sc/0323), within 30 minutes of delivery. Placental villous fragments 
were cultured in buffered solution with or without 20 µM 25-hydroxyvitamin D [25(OH)D] (for detailed 
methods, see Online Supplementary Material). The placental samples were snap frozen and stored at -
80°C. DNA was extracted, and DNA methylation was measured using the Illumina EPIC 850k array. 
CpGs in which DNA methylation was altered were identified using a Wilcoxon signed-rank test. RNA 
was also extracted, and stranded RNA sequencing was performed; differentially expressed genes 
following 25(OH)D treatment were identified. In human placental villous fragments, 25(OH)D 
treatment altered DNA methylation at 6 CpG sites in the RXRA gene (decreased at four CpG sites (-
0.80% to -2.67%, p=0.04 and 0.02, respectively) increased in two (1.10% to 1.41%, p=0.04 and 0.01, 
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respectively), as shown in Online Supplementary Table 6. Through RNA sequencing, RXRA gene 
expression was shown to increase following 25(OH)D treatment (log fold change 0.50, p=0.04).  
 
Discussion 
In this study we have demonstrated, to our knowledge for the first time in a randomised controlled trial 
setting, that supplementation with cholecalciferol in pregnancy is associated with reduced methylation 
at specific regions near to the RXRA promoter in fetal DNA derived from the umbilical cord of the 
offspring. Percentage methylation levels measured by pyrosequencing were lower in the cholecalciferol 
supplemented group than the placebo group (statistically significantly at the cluster of CpG sites 
represented by CpG 5), raising the possibility of site-specificity for a molecular interaction between 
25(OH)D in pregnancy and DNA methylation.(21)  
These results are consistent ZLWKRXUSUHYLRXVREVHUYDWLRQDO ILQGLQJV LQ WKH6RXWKDPSWRQ:RPHQ¶V
Survey, in which a negative association was found between an estimate of maternal free 25(OH)-
vitamin D and RXRA methylation at CpG 4/5,(5) measured using the Sequenom MassARRAY 
EPITYPER. Additionally, the associations between RXRA methylation and neonatal bone indices in the 
placebo group replicated those observed previously in the SWS; conversely, in the present study, the 
direction of the association appeared to be reversed (albeit not reaching statistical significance) in the 
group whose mothers were supplemented with cholecalciferol. It is interesting that the methylation 
difference between treatment and placebo groups in the present study was greater in summer than winter 
births. The increase in 25(OH)D from baseline to 34 weeks was markedly greater for summer than 
winter deliveries, although the absolute difference between groups at 34 weeks was marginally less in 
summer than winter, suggesting that greater increases in 25(OH)D across pregnancy might facilitate 
methylation differences consequent to vitamin D supplementation. However, given that RXRA interacts 
with several different nuclear hormone receptors, such as thyroid hormone receptor and PPAR-gamma, 
activation of either of which tends to have detrimental effects on bone, it is possible that we are seeing 
the net result of a complex series of inter-relationships at this molecular level, with exogenous vitamin 
D perhaps modifying the balance in RXRA interaction between receptor types, resulting in 
heterogeneous associations between RXRA methylation and bone indices. Such considerations may be 
relevant both to the skeletal and to the seasonal differences we observed, although ultimately these 
questions must remain the focus of future research. Interestingly, we observed no consistent 
associations between maternal 25(OH)D in late pregnancy and RXRA methylation, but these measures 
were in different tissues, 6 weeks apart, and we were able to directly test whether treatment of perinatal 
tissue (placenta) with vitamin D would alter RXRA methylation. Thus, consistent with the findings from 
the MAVIDOS trial, in a small study of human placental villous fragments RXRA methylation appeared 
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to be lowered at several CpG sites by the addition of 25(OH)D, and indeed RXRA expression 
upregulated overall, suggesting a specific role the vitamin D-RXRA interaction.  
Although the exact nature of the mechanistic underpinnings of our findings remains to be elucidated, 
there are several routes by which maternal 25(OH)D status might influence perinatal RXRA methylation. 
As previously stated, RXRA forms a heterodimer with several nuclear hormones known to influence 
bone metabolism, including 1,25(OH)2-vitamin D, perhaps implying that maternal 25(OH)D status 
plays a permissive role in the transcriptional regulation of the RXRA gene. Studies have shown that 
vitamin D may interact with the epigenome on multiple levels,(17, 22-25) and our evaluation of public data 
from ENCODE suggest that methylation at the studied CpG sites is likely to have functional relevance, 
with evidence for DNase I hypersensitive regions, enhancer activity and transcription factor binding. 
Furthermore, this suggested function within the DMR, which itself resides within the shore region of 
WKH¶&S*LVODQG7KLVORFDWLRQKDVEHHQDVVRFLDWHd with influence on gene expression.(26) Epigenome-
wide association studies (EWAS) have also provided some insight into the actions of vitamin D on 
DNA methylation.  A small EWAS of DNA methylation in severely vitamin D deficient African-
American adolescents demonstrated associations between vitamin D status and methylation in several 
genes, including genes involved in vitamin D metabolism such as the 24 and 25-hydroxylase genes. In 
the context of low serum vitamin D levels, the promoter of CYP2R1 may become methylated, and this 
is reversible on exposure to vitamin D.(27) Other studies have assessed the DNA methylation in CYP 
enzymes which are part of the vitamin D metabolism pathway, and found a relationship between 
methylation of the genes CYP2R1 (25-hydroxylase) and CYP24A1 (24-hydroxylase) and variations in 
circulating 25(OH)D levels.(28) However, a study using the ALSPAC cohort and the Norwegian Mother 
and Child Cohort (MoBa) in which maternal 25(OH)D was measured in mid-pregnancy, demonstrated 
no convincing associations between maternal 25(OH)D status and DNA methylation in the umbilical 
cord blood (as opposed to umbilical cord tissue in our study) of 1,416 newborn babies using Illumina 
450k DNA methylation array analysis, thereby covering 473,731 CpG DNA methylation sites.(29) The 
authors suggested that to further identify associations, larger consortium studies, expanded genomic 
coverage, and investigation of alternative cell types or 25(OH)D status at different gestational time 
points might be needed.   
The data presented are from a placebo-controlled, double-blind, randomised trial, using the gold 
standards of pyrosequencing to determine CpG site-specific DNA methylation and DXA to assess bone 
mass. However, the limitations of our study must be considered. Firstly, we have analysed methylation 
in cells from whole umbilical cord; therefore it is possible that the differential methylation we observed 
arose from different component cells in individual samples (e.g. fibroblasts and epithelial cells). The 
difference in DNA methylation between treatment and control groups may thus partly reflect different 
proportions of cells and their cell-specific DNA methylation.  However, any unaccounted cell-
heterogeneity may represent proportional differences that are related to the observed phenotypic 
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outcomes,(30, 31) and so potentially on the causal pathway. Secondly, owing to stipulations made during 
the ethics approval process, participants with baseline 25(OH)D concentrations less than 25nmol/L or 
greater than 100nmol/l could not be included. In addition, the study population did not include many 
women who were of non-white ethnicity, which again would affect the generalisability of our findings 
to a multi-ethnic populations. Third, DXA assessment in neonates presents some difficulties, both due 
to the low absolute BMC of newborn babies and their tendency to move. However, the validity of DXA 
in small animals, of comparable size to neonates, has been documented (32) and appropriate DXA 
software was used. Fourth, some participants were taking vitamin D supplements in addition to the 
study drug, though supplement use was recorded at interview and did not differ between the treatment 
groups. Fifth, though we have previously excluded the presence of any SNPs at the CpG sites of interest 
at the RXRA locus by sequencing, we did not have information permitting exclusion of a genetic cis or 
trans-effect of local or distant SNPs, respectively. These could influence either associations between 
vitamin D supplementation and RXRA methylation, or influence both RXRA PHWK\ODWLRQDQGWKHFKLOG¶V
bone phenotype. Sixth, we did not have measurements of 25(OH)D in umbilical cord blood and thus 
were not able to directly assess a potential mediating role for 25(OH)D for RXRA methylation in the 
same organ at the same time. Finally, it should be noted that the analysis is post hoc and that methylation 
outcomes were not pre-specified in the original analysis plan, and so will require replication in further 
intervention studies.  
In conclusion, we have shown in a randomised controlled trial that maternal supplementation with 
cholecalciferol from 14 weeks gestation to delivery leads to lower levels of DNA methylation at the 
RXRA promoter in umbilical cord. This informs our understanding of early life mechanisms 
underpinning maternal vitamin D status, epigenetic change and bone development, and may suggest a 
QRYHOELRPDUNHUIRUDFKLOG¶VIXWXUHERQHKHDOWK 
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Figure legends 
 
Figure 1: MAVIDOS Trial Consort Diagram 
 
Figure 2: Difference in RXRA DNA methylation at each CpG site between Cholecalciferol 1000 IU/day 
supplemented group and placebo group (expressed as Standard Deviations). Each bar is the outcome of 
a separate linear regression (mean difference and 95%CI). 
 
Figure 3: Associations between RXRA methylation at CpG 5, CpG 11 and CpG 12 and whole body 
minus head bone area (cm2), bone mineral content (g), bone mineral density (g/cm2), percentage bone 
mineral content (%), and size-corrected bone mineral content (g), adjusted for sex, by treatment group 
(placebo [red bars] or 1000 IU cholecalciferol daily [blue bars]). Outcomes expressed per 10% increase 
in methylation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
18 
This article is protected by copyright. All rights reserved 
Table 1a: Baseline characteristics of the randomly assigned pregnant women included in the analysis. Values are n (%), mean (SD) or median (IQR). 
(P-difference 25(OH)D at 34 weeks, cholecalciferol supplemented vs. placebo group, p <0.001) 
 n Placebo (N=228) Cholecalciferol 1000 IU/day 
(N=225) 
mean (SD) or median (IQR)    
Age (years) 427 30.9 (5.2) 30.7 (5.1) 
Height (cm) 423 166.4 (6.3) 165.3 (6.1) 
Weight (kg) 427 73.6 (13.1) 71.6 (14.1) 
Pregnancy weight gain (kg) 415 9.4 (3.6) 9.7 (3.5) 
BMI, (kg/m2 423 25.7 (23.0,29.7) 24.9 (22.4,28.8) 
Sum of skinfold thickness (mm) 360 81.9 (27.0) 78.3 (29.1) 
25(OH)D at 14 weeks, (nmol/l) 445 45.1 (16.2) 44.4 (15.2) 
25(OH)D at 34 weeks, (nmol/l) 432 42.8 (20.0) 66.3 (19.8) 
    
n(%)    
Nulliparous 427 99 (46.3) 91 (42.7) 
Educational qualification>A level 423 156 (74.3) 163 (76.5) 
Current smoker 426 16 (7.5) 12 (5.7) 
6WUHQXRXVH[HUFLVHRQFHDZHHN 390 22 (11.3) 32 (16.4) 
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Table 1b: Whole body minus head DXA characteristics of the MAVIDOS babies by sex for whom DXA and RXRA methylation data are available. p-values 
< 0.05 are in bold. 
 Boys (n=201) Girls (n= 174) p difference 
between boys 
and girls 
Gestational age (weeks) 40.3 (1.2) 40.1 (1.4) 0.080 
BA (cm2) 306.5 (34.9) 295.8 (33.8) 0.003 
BMC (g) 63.1 (10.8) 59.9 (10.5) 0.004 
aBMD (g/cm2) 0.205 (0.018) 0.202 (0.020) 0.100 
 
BA: bone area; BMC: bone mineral content; aBMD: areal bone mineral density. 
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Table 1c: Whole body minus head DXA characteristics of the MAVIDOS babies by maternal randomisation group for whom DXA and RXRA methylation 
data are available. p-values < 0.05 are in bold. 
 
 Placebo (N=185) Cholecalciferol 1000 
IU/day (N=190) 
p difference 
between 
maternal 
randomisation 
group 
Gestational age (weeks) 40.1 (1.4) 40.2 (1.3) 0.46 
BA (cm2) 299.4 (36.7) 303.6 (32.6) 0.24 
BMC (g) 61.2 (10.9) 62.0 (10.6) 0.46 
aBMD (g/cm2) 0.204 (0.019) 0.203 (0.019) 0.93 
 
BA: bone area; BMC: bone mineral content; aBMD: areal bone mineral density.  
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Table 2: RXRA DNA methylation in cholecalciferol 1000 IU/day supplementeda and placebob groups. p-values < 0.05 are in bold. q-values were obtained 
using the Simes method. 
 
 
CpG 5 represents CpGs 1-5; CpG 11 represents CpGs 8-11. 
 
 
 
 
 
CpG 
 
n 
 
% methylation 
Cholecalciferol 
1000 IU/daya 
% methylation 
Placebob 
 
Mean difference 
% methylation (a-b) 
95%CI 
 
p difference 
 
q difference 
RXRA  CpG 5 447 46.7 (8.2) 48.7 (9.7) -1.98 -3.65, -0.32 0.02 0.06 
RXRA  CpG 11 446 58.3 (7.5) 58.9 (8.1) -0.67 -2.12, 0.78 0.36 0.36 
RXRA  CpG 12 446 66.1 (5.8) 66.9 (6.6) -0.84 -1.99, 0.31 0.15 0.225 
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Table 3: RXRA DNA methylation in cholecalciferol 1000 IU/day supplemented and placebo groups, stratified by season: winter births (December-May) and 
summer births (June-November).  
 
 
 
 
 
 
Difference in methylation = mean(cholecalciferol 1000IU/day) - mean(placebo). To assess differences in % methylation between two groups, t-test used 
(variables normally distributed). p-values < 0.05 are in bold. q-values were obtained using the Simes method. 
 
 
 
 
  
 
Winter births (Dec-May) Summer births (June-Nov) 
CpG  Mean diff. % 
methylation  
95%CI p q Mean diff. % 
methylation  
95% CI p q 
RXRA  CpG 5 0.27 (-2.27,2.82) 0.83 0.83 -3.69 (-5.92,-1.45) 0.001 0.003 
RXRA  CpG 11 1.51 (-0.73,3.76) 0.19 0.57 -2.38 (-4.29,-0.47) 0.02 0.02 
RXRA  CpG 12 0.79 (-1.00,2.58) 0.38 0.57 -2.13 (-3.60,-0.65) 0.005 0.0075 
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Table 4: Relationships between perinatal methylation in umbilical cord at CpG sites within the RXRA region of interest and bone indices at birth (measured 
by DXA, whole body minus head). BA: bone area; BMC: bone mineral content; aBMD: areal bone mineral density. 
Associations are adjusted for sex and treatment group. ȕFRHIILFLHQWVand 95% CIs have been multiplied by 10 and therefore represent the change associated 
with a 10% increase in methylation. p-values < 0.05 are in bold.  
 
 
 
 
 
 
 
 
  
 
 
 
  
RXRA CpG  BA, (cm2) BMC, (g) aBMD, (g/cm2 )  
  ȕ&, p ȕ&, p ȕ&, p 
CpG 5 4.16 (0.14, 8.18) 0.043 1.50 (0.26, 2.73) 0.018 0.002 (0.000, 0.004) 0.047 
CpG 11 2.72 (-1.98, 7.42) 0.256 0.83 (-0.63, 2.28) 0.265 0.001 (-0.002, 0.004) 0.478 
CpG 12 2.75 (-3.27,8.78) 0.37 0.59 (-1.28, 2.45) 0.535 0.000 (-0.003, 0.003) 0.925 
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Figure 1 
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Figure 2 
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Figure 3 
